Inherited metabolic disorders account for a small but significant number of sudden unexplained deaths in neonates, infants and occasionally older children. In particular, inherited disorders of fatty acid oxidation may closely mimic sudden infant death syndrome. Post-mortem investigations offer the final opportunity to establish a diagnosis. Such diagnoses are of great importance to the families concerned and provide the opportunity for genetic counselling and antenatal diagnosis. Current advances in technology, particularly in the case of electrospray ionization tandem mass spectrometry, have revolutionized the investigation of metabolic disease at post-mortem, facilitating the identification of a wide range of metabolic diseases in tiny samples of blood, plasma and bile. Such analyses may provide vital clues to diagnosis, usually in the form of acylcarnitine profiles. Accurate diagnosis relies on the timely collection of appropriate samples and the subsequent selection of informative testing. In order to maximize the chances of a diagnosis, a collaborative approach between the various disciplines is vital. A brief description of the more frequently encountered inherited disorders, collection and processing of appropriate samples and available investigations that may lead to accurate diagnosis are clearly described.
Introduction
Garrod in 1909 used the term 'inborn errors of metabolism' in de¢ning a spectrum of genetically inherited disorders characterized by blocks in the metabolic pathway.
1 While Garrod only described four such disorders that were known at the time, our current knowledge of the human genome has expanded such that there has been a vast increase in the number of diseases de¢ned and which may now be diagnosed. However, inherited metabolic disease that results in premature death is still sadly under-diagnosed. 2 While in the USA the concept of 'the metabolic autopsy' is now well recognized, 3 here in the UK uncertainties and confusion remain as to which samples should be taken, how these should be processed and the nature of investigations that are currently available. It is primarily the application of mass spectrometry to clinical biochemistry 4, 5 coupled with current advances in molecular genetics that has opened up the possibilities for diagnosis in a wide range of disorders.
Public awareness of the issues surrounding sudden infant death syndrome (SIDS) has served to highlight the importance of collecting and storing appropriate samples that can, if necessary, be reinvestigated at a later date. Metabolic disorders have profound e¡ects, not only on patients and their immediate family, but also on the long-term reproductive health of that family, often with implications for the extended family. Only by accurate diagnosis can appropriate genetic counselling and antenatal diagnosis be made available to the families concerned.
The investigation of suspected metabolic disease when there is sudden death of unknown cause, or where investigations in life have not resulted in a diagnosis, requires a coordinated plan of action. The importance of good clinical liaison between the di¡erent disciplines in facilitating appropriate investigations and in conserving precious postmortem samples cannot be over-emphasized. Clinical scientists should be in a position to advise on, or at least to know to whom to refer for expert advice, questions relating to the collection of appropriate samples and the types of investigations that are available in cases of suspected metabolic disease.
Many inborn errors of metabolism can present as acute metabolic disease in the newborn period. Most babies with inherited metabolic disorders are born apparently healthy and may show a typical asymptomatic period with clinical manifestation from the second day of life onwards. However, some disorders may present at birth or may be detected by antenatal ultrasonography. Sadly many babies with inherited metabolic disease follow a rapid course of deterioration and may succumb before appropriate investigations can be undertaken. The pattern of deterioration may be a useful indicator of the underlying disorder (seeTable1). 6 The intention of this article is to provide a brief description of the metabolic disorders that are more likely to be encountered in the context of unexplained sudden death, or death following a brief illness, in neonates and older infants. The subsequent collection and processing of appropriate samples and types of investigations that are currently available are clearly described.
Sudden infant death syndrome (SIDS)
SIDS is the unexpected death of an apparently well infant over 1 month of age, for which no cause can be found in spite of a post-mortem examination. 7 The precise cause of such sudden unexplained death in infants under 1 year of age remains unknown in approximately 80% of cases. 8 Of the known causes, infections account for the highest number of 'natural' causes. 9, 10 The diagnosis of SIDS or sudden unexplained death in infancy still remains the largest single cause of death in children in the industrialized world. The frequency is reported at 1:1000 live births and represents 25% of all deaths in the ¢rst year of life. Current and future advances in our understanding of human biology along with increasingly sophisticated technology are likely to lead to the recognition of new disorders that may result in sudden death in a previously 'well' infant, and, provided that stored material is available for future investigation, an opportunity for retrospective diagnosis remains. The recent high-pro¢le cases of mothers wrongly imprisoned for infanticide highlights the importance of the opportunity to re-investigate specimens taken at post-mortem. This may be crucial for the family concerned.
Although the majority of SIDS is due to unknown cause(s), it is recognized that a small but signi¢cant number of sudden deaths in infancy and occasionally in older children are a result of inherited metabolic disease. Emery was the ¢rst to observe that a wide range of metabolic disorders may present as 'sudden infant death syndrome'. 11 It may result from dramatic cardiac failure, shock or cardiac arrest in many metabolic circumstances. Although critical review may suggest that not all these deaths were entirely unexpected, they were initially unexplained. Identi¢cation of the cause of death in such cases is consolation to parents and o¡ers the opportunity for future prenatal diagnosis. Although at least 31metabolic disorders are listed as causes of SIDS, there is some doubt as to the validity of some reports. 12 The most likely metabolic causes of sudden unexplained death are:
. In practice, with the exception of the FAO defects, the majority of these disorders do not strictly present as SIDS but rather as an acute metabolic crisis with clear clinical symptoms, which precedes death by hours or even a few days.
Non-accidental injury
It is recognized that a number of inherited defects can present in such a way that they may be misinterpreted as being due to non-accidental injury. 
Metabolic causes of sudden death
The most common group of metabolic disorders presenting as sudden unexplained death in infancy are the FAO disorders. It is estimated that up to 3-6% of sudden unexpected infant deaths are attributable to this group of disorders. 20^23 Defects of medium-chain acyl-CoA dehydrogenase (MCAD), carnitine palmitoyltransferase type II, carnitine-acylcarnitine translocase, the high-a⁄nity carnitine transporter (mutations of the gene OCTN2, causing primary carnitine de¢ciency), long-chain 3-hydroxyacyl-CoA dehydrogenase, mitochondrial trifunctional protein, very-long chain acyl-CoA dehydrogenase and multiple acyl-CoA dehydrogenase have all been reported as presenting initially as cases of sudden unexplained death. 2, 21 However, of the FAO defects, MCAD de¢-ciency is the single most common disorder and warrants further description.
MCAD deficiency
MCAD de¢ciency was ¢rst described in the early 1980s, 24, 25 north-western European origin with an incidence as high as 1:8000 live births. The ¢rst crisis is fatal in up to 25% of cases, patients classically presenting with hypoketotic hypoglycaemia. 26 However, a signi¢cant percentage of genetically predisposed patients remain asymptomatic throughout life. 26, 27 The disease is primarily of hepatic FAO. Clinically, patients may present with lethargy, emesis, encephalopathy, respiratory arrest, hepatomegaly, seizures, apnoea and cardiac arrest. 26, 28 Although hypoglycaemia with 'inappropriate' hypoketosis is usually the major presenting biochemical feature, some patients may present with hypotonia and reduced consciousness while still maintaining blood glucose concentration within the normal range. Patients presenting in crisis may often have detectable ketones in their urine. Indeed, there is evidence to suggest that, at least in the well child with MCAD de¢ciency, medium chain FAO and ketone body production and utilization are within normal limits. 29, 30 Rarely, MCAD de¢ciency patients may present in crisis with'paradoxically'gross ketosis (J Calvin, personal communication). Some patients presenting initially as SIDS have subsequently on biochemical testing been shown to have MCAD de¢-ciency. 31 Babies can present within the ¢rst few days of life as a sudden death. 32, 33 Mean age at presentation is 12 months, but presentation after the age of 5 years is rare, 26 although there are isolated reports of adult presentations following extreme metabolic stress. 34, 35 The common K304E mutation accounts for 85% of this disease in most of western Europe. 36 Neonatal screening programmes which now include MCAD de¢ciency are in place in a number of countries including Australia, some states in the USA and a number of European countries. At present there is no national screening programme for MCAD de¢ciency in the UK, but a pilot study involving ¢ve UK centres is underway.
Other FAO defects
Following the description of MCAD de¢ciency, there has been considerable growth in our knowledge of previously undescribed FAO defects, with some 15 or so defects that directly or indirectly a¡ect FAO having been reported. 37 This group of disorders is now widely recognized as being an important cause of acute metabolic decompensation and sudden death in the neonatal period, infancy and early childhood. 38 Cumulatively, these other disorders probably account for a similar number of sudden deaths as does MCAD de¢ciency. Two main types of presentation are most commonly observed. The ¢rst is characterized by hypoketotic hypoglycaemia after a period of prolonged fasting. Patients may present acutely with a lifethreatening illness, which may rapidly proceed to coma and death during intercurrent infections, surgery or other catabolic stress, having apparently been previously well or having only exhibiting mild symptoms such as failure to thrive. Additionally, there may be liver disease with hyperammonaemia and cerebral oedema (Reye-like illness). Cardiac arrhythmias resulting in sudden death may be induced by accumulation of long-chain acylcarnitines, which are particularly arrhythmogenic, and there may be acute cardiomyopathy with pericardial e¡usion. 38 The second presentation re£ects chronic impairment of muscle function with myopathy and/or cardiomyopathy, which can be either hypertrophic or dilated. Sudden death as a result of severe cardiomyopathy has been reported in patients previously thought to be well. 39 Defects of ketone body production/utilization 3-Hydroxy-3-methylglutaryl-CoA lyase is an enzyme required for ketogenesis as well as for the last step in leucine oxidation. Patients with de¢ciency of this enzyme present in infancy or early childhood with life-threatening Reye-like crisis; the picture is one of hypoketotic hypoglycaemia, metabolic acidosis and liver disease. Analysis of urine organic acids gives a speci¢c pattern of abnormal metabolites.
3-Ketothiolase (mitochondrial 2-methylacetoacetylCoA thiolase) is a ketolytic enzyme but is also an enzyme of isoleucine metabolism. Patients with a de¢ciency of this enzyme usually present in infancy between 6 and 24 months of age, but occasionally as older children, with episodes of vomiting often precipitated by intercurrent infection or occasionally by high protein intake. There is acute life-threatening ketoacidotic crisis with severe metabolic acidosis, occasionally low, but usually normal glucose and normal or moderately raised ammonia. Patients may rapidly succumb to overwhelming metabolic acidosis. Urine organic acid and blood acylcarnitine analysis will identify this disorder.
Urea cycle defects
Defects of the urea cycle may present in the neonatal period, infancy and childhood or in adolescents and adults; cumulatively they have an incidence of 1:20 000. Hyperammonaemia is a potent cause of cerebral oedema in this group of patients. The presentation at di¡erent age groups shows some variability but it is particularly in neonates and infants where the presentation may be of a sudden acute decompensation rapidly proceeding to coma and death. Neonates typically present on day 2 of life, following a brief asymptomatic period. There is usually disinterest in feeding, lethargy, hyperventilation, seizures and progressive encephalopathy and coma with loss of re£exes and frequently intracranial haemorrhages resulting from coagulation defects. Respiratory alkalosis develops with marked hyperammonaemia. A misdiagnosis of sepsis is frequently made. 40, 41 Diagnosis, depending on the defect, is by amino acid analysis in plasma and urine, demonstration of elevated argininosuccinic acid in urine in the case of argininosuccinate lyase de¢ciency, increased orotic acid in urine in OTC de¢ciency, followed by enzyme studies in leucocytes, ¢broblasts or liver and/or mutation studies.
Organic acidurias
This large group of disorders result from defects of intermediary metabolism with the characteristic accumulation of carboxylic acids in urine. The majority of the important organic acidurias are caused by disorders involving the metabolism of branchedchain amino acids. Patients classically present in the neonatal period with metabolic encephalopathy resulting from 'metabolic intoxication' (see Table 1 ). There is lethargy, feeding problems, dehydration and limb hypertonia with truncal hypotonia. Patients show multisystem failure, neurovegetative dysregulation and coma. These disorders include IVA, PA, MMA and multiple carboxylase de¢ciency. The multiple carboxylases are biotin-dependent enzymes important in the metabolism of branched-chain amino acids, and disorders of these enzymes encompass biotinidase de¢ciency, holocarboxylase synthetase de¢ciency and 3-methylcrotonylglycinuria.
GA-I (glutaryl-CoA dehydrogenase de¢ciency) is a disorder of lysine and tryptophan metabolism. Patients are normal at birth but usually present during infancy or early childhood with acute encephalopathic crisis and metabolic decompensation during intercurrent infection or other metabolic stress. There is often macrocephaly with frontotemporal atrophy. The ¢rst episode may be fatal, but those patients that survive are left with severe dystonic^dyskinetic movement disorder; intellect, however, is frequently intact. Patients presenting with this condition may be mistaken as cases of possible non-accidental injury (see section on non-accidental injury).
Mitochondrial respiratory chain disorders
Mitochondriopathies are disorders of enzymes or enzyme complexes that are directly involved in the production of chemical energy by the process of oxidative phosphorylation. These include PDH complex and the respiratory chain complexes, including ATP synthase. These disorders lead to a wide spectrum of clinical disease. Almost any organ or system can be a¡ected; often a combination of seemingly unrelated symptoms with clinical disease in several tissues suggests the possibility of respiratory chain disease. 42 Cardiac disease in infants and older children is often a result of genetic defects of oxidative phosphorylation and may present as an isolated cardiomyopathy or with other multiorgan involvement. Some infants with respiratory chain disease die early in the neonatal period and many of these are not fully investigated in life.
Disorders of galactose and fructose metabolism
Patients with classical galactosaemia resulting from galactose-1-phosphate uridyltransferase de¢ciency or hereditary fructose intolerance only develop clinical symptoms of disease after ingestion of lactose (milk and dairy products) or fructose/sucrose, respectively. Galactose 1-phosphate and fructose 1-phosphate, which accumulate in classical galactosaemia and hereditary fructose intolerance, are toxic metabolites that lead to organ damage, particularly in the liver, kidneys and brain. Galactosaemia usually presents in the neonatal period on commencement of milk feeds and is frequently fatal unless detected at an early stage. Hypoglycaemia with jaundice, deranged liver function and renal failure are the common features, often with accompanying sepsis. Patients may succumb with the incorrect primary diagnosis of sepsis. Diagnosis for galactosaemia is by enzyme assay in whole blood or on a fresh Guthrie card blood spot, quantitation of galactose 1-phosphate in erythrocytes, or by mutation detection. Blood transfusion will of course invalidate the enzyme assay in blood.
Hereditary fructose intolerance may present with similar features to galactosaemia at the time of weaning with the ¢rst introduction of fructose-containing feeds. Patients present with hypoglycaemia, vomiting, progressive liver dysfunction with hepatomegaly, renal tubular damage and coma. Diagnosis is by demonstration of reducing substance in the urine (fructose) and often by demonstrating the presence of the common A149P mutation in the aldolase B gene. Galactosaemia and hereditary fructose intolerance show similar pathological changes, such as fatty change in the liver, giant cell transformation, pseudoacinar arrangement of hepatocytes and cirrhosis.
Fructose-1,6-bisphosphatase de¢ciency results in severely impaired gluconeogenesis. Neonatal presentation of this disorder follows a precipitous and often lethal course. There is hypoglycaemia, hyperventilation, ketosis, lactic acidosis, apnoea, seizures and cardiac arrest. However, infants that are rapidly treated with glucose and bicarbonate may then remain symptom-free for weeks or months before having a further attack. Episodes in older infants are often triggered by fasting and febrile episodes. There is frequently mild hepatomegaly, and urinary organic acids contain glycerol, glycerol 3-phosphate and 2-ketoglutaric acid. Con¢rmation is by enzyme assay in liver or by mutation analysis of the aldolase A gene.
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Glycogen storage disease GSD invariably presents either with pathological accumulation of glycogen (e.g. isolated hepatomegaly) and corresponding organ dysfunction (e.g. liver disease/myopathy), or with hypoglycaemia. The enzyme defect is frequently organ-speci¢c and there may therefore be primary hepatopathic, myopathic or mixed symptoms. The cumulative incidence of GSD is 1:20 000. Patients may present in early infancy with hypotonia and severe cardiomyopathy (GSD type II, Pompe disease) or with hypoglycaemic seizures, recurrent hypoglycaemia with acidosis, truncal obesity, hepatomegaly, nephromegaly, muscle atrophy and bleeding tendency (GSD type I). Infants with GSD-I may present in acute hypoglycaemic crisis with lactic acidosis which may rapidly proceed to death. Diagnosis is con¢rmed by biopsy with enzyme studies or mutation analysis.
Post-mortem findings
A coordinated plan of investigation should include accurate details of clinical and family history. Information on ethnicity, consanguinity and previous obstetric history followed by physical examination and preliminary post-mortem ¢ndings should be assessed. This information, together with results from any pre-mortem biochemical and haematological testing, may provide important clues that may help to direct the selective use of appropriate laboratory analysis. Clearly, unexplained death in an infant or child can be due to a number of non-metabolic causes and these of course also need to be excluded. Any unexplained sudden death will include an infective cause as a key part of the di¡erential diagnosis and this needs to be excluded where possible.
Features that may suggest a metabolic cause of death include a range of dysmorphic features, some of which may suggest a speci¢c diagnosis (e.g. microcephaly, micrognathia, anteverted nostrils, syndactyly of second and third toes strongly indicating the possibility of Smith-Lemli-Opitz syndrome) (seeTable 1). However, dysmorphology, particularly if it is subtle, is best assessed by a clinical geneticist. It is therefore important to undertake an external examination, which must include careful evaluation of any dysmorphic features. Newer techniques such as magnetic resonance imaging (MRI) may allow targeted biopsies in cases with limited consent, and in the future some of the subtle internal changes (e.g. cerebral dysgenesis, agenesis of the corpus callosum and congenital heart anomalies) may be amenable to detection by post-mortem MRI. In cases of early neonatal death, assessment of the placenta may also yield vital information; for example, vacuolation of the syncytiotrophoblast may arise in a number of storage disorders. Examination of tissue samples for fat deposition at an early stage of the post-mortem may give an indication for further investigations; for example, coarse vacuolation of renal tubular epithelium with fat deposition in proximal renal tubules is highly suggestive of a fat oxidation defect. Storage material in various organs and/or tissues may also o¡er other vital clues to a diagnosis.
Samples
The collection of appropriate samples at post-mortem is of paramount importance in the investigation of metabolic disease. All too frequently further investigations are requested in cases of unexplained death but appropriate samples are not available. It is essential to collect representative post-mortem samples and to discuss their analysis with a metabolism specialist. Appropriate investigations on often very small samples of body £uids and tissues must be well coordinated if precious material is not to be used up unnecessarily. In cases of expected death, whenever possible collect samples of blood, urine and tissues prior to death. This applies especially to skeletal muscle biopsies and cerebrospinal £uid (CSF) for the investigation of suspected mitochondrial respiratory chain disease, as samples collected after death are highly susceptible to post-mortem deterioration. Liver and other internal tissues undergo proteolysis quickly after death. Changes are apparent in mitochondria within 2 h, and respiratory chain enzyme activity deteriorates rapidly. Consequently, for the purpose of many biochemical analyses, liver, heart and skeletal muscle biopsies must be taken promptly if accurate results are to be obtained. Unless an autopsy is going to be conducted immediately, biopsies of internal organs for enzyme analysis, especially those for respiratory chain assay, should be done soon after death. Small open muscle and open liver biopsies are easily obtained. However, some enzymes of intermediary metabolism are more stable, so biopsies of liver, muscle, heart, kidney and even brain may still provide essential diagnostic or con¢rmatory information, even when obtained a day or two after death during a routine autopsy.
It is of paramount importance to obtain a biopsy for ¢broblast culture, as many of the enzymes known to be de¢cient in inborn errors of metabolism are expressed in ¢broblasts, and this will frequently be the only tissue where an enzyme con¢rmation of a suspected diagnosis can be made. Cultured ¢broblasts also provide important reference material for future prenatal diagnosis for the family concerned as these cells can be cryopreserved for an inde¢nite period in liquid nitrogen.
Urine
This should be collected by catheterization or suprapubic puncture into a container with no preservative. As little as 100 mL can be su⁄cient for organic acid analysis by gas chromatography-mass spectrometry (GC-MS). If the sample is contaminated with blood, centrifuge the sample to remove the cells prior to freezing the urine at 7208C.Washing out the bladder with a small volume of sterile saline may also yield enough sample for organic acid analysis.
Blood
Liquid blood is frequently obtainable by cardiac puncture up to several days after death. If only small quantities of blood are available, however, whole blood acylcarnitine analysis is likely to be single most informative test that can be performed in spite of the potential problems of interpretation 2 (see section on investigations). Spot a few drops of whole blood onto a ¢lter paper (i.e. a Guthrie card), as this is the most convenient method of collection and importantly most suitable for uniformity of analytical technique. If more blood is available (in addition to the Guthrie card), collect up to 10 mL of heparinized blood as this can be separated and the plasma stored at 7208C; the cells should be stored at +48C (do not freeze). If DNA analysis is likely to be required, collect a further 5 mL of whole blood (EDTA) and freeze immediately (at least 7208C) until DNA is required. Collect also 5 mL of blood into a £uoride oxalate tube for the measurement of intermediary metabolites; this collection, however, is only applicable to samples taken before or very soon after death.
CSF
CSF may be useful in certain circumstances (e.g. organic acid analysis, acylcarnitine analysis), but is often only reliably informative (e.g. analysis of certain amino acids), if collected prior to death. Collect two 1-mL samples, one into a plain tube and one with £uoride oxalate, and store these immediately at 7808C.
Vitreous humour
This can be collected into a £uoride bottle by needle aspiration and stored at 7208C.
Bile
Bile may be the only available analysable £uid in cases where the interval between death and post-mortem has been protracted. It is recommended that, in all cases where there is the possibility of underlying metabolic disease, a sample of bile should be obtained. Bile is most conveniently spotted onto a Guthrie card for acylcarnitine pro¢ling. If a Guthrie card is not available, bile can be collected at post-mortem into a plain tube for storage at 7208C.
Skin or other samples for culturing fibroblasts
A skin biopsy should be a routine part of all postmortem investigations if an infant or child has died from unknown cause. Sterility is of paramount importance when taking a skin biopsy. Ideally, two punch biopsies taken from di¡erent sites and placed in separate sterile vials containing appropriate culture medium (Ham's F10, Eagle's minimum essential medium, Dulbecco's medium) is the preferred option. It is recommended that all pathologists who undertake paediatric post-mortems should invest in a biopsy punch. In the absence of a punch, it should be borne in mind that small biopsies carry a lower risk of infection, two 3 mm63 mm full-thickness biopsies are all that is required. Large pieces of skin and tissue frequently fail because of infection. It is recommended that the skin biopsy be taken at the beginning of the post-mortem to reduce the risk of contamination. Skin ¢broblasts remain viable for 2-3 days after death, and in some cases up to a week. However, the biopsy should be obtained as soon as possible, as this increases the likelihood of a successful culture. The addition of Fungizone to the culture medium can help to reduce the risk of fungal infections, but it is no substitute for good aseptic technique. Alternatively, where infection is likely to be particularly problematic or where there has been a post-mortem delay of some days and viability is likely to be low, it is worth taking small biopsies from a number of separate sites (e.g. pericardium, fascia and/or cartilage) into separate containers to increase the chances of successful culture. Once the biopsies have been taken they should be sent immediately to the cell-culture laboratory, but can if necessary be stored overnight at +48C (do not freeze as this will destroy any viable cells) prior to dispatch. In an emergency, sterile normal saline can be used instead of culture medium, but do not use agar.
Tissue samples for biochemical analysis
The selection of organ biopsies depends on the clinical picture and is best discussed with a metabolism specialist. Liver, heart muscle, skeletal muscle and kidney are usually only suitable for biochemical analysis if taken within 2-4 h of death. Open biopsies are preferable but, if this is not possible, two or three needle biopsies should be taken. All such biopsies for biochemical analysis should be wrapped in aluminium foil and snap-frozen in liquid nitrogen or solid carbon dioxide. The samples should then be stored in a freezer at 7808C.
Tissue samples for histological examination Liver
A small piece of liver is collected into formalin for staining and light microscopy and a piece into glutaraldehyde for electron microscopy.
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Kidney A piece of kidney should be taken for fat stain.
Muscle biopsy
Take a small piece for formalin ¢xation and para⁄n preparation (do not freeze); this is for light microscopy. Also, a thin muscle ¢bre, tied to a stick (to avoid contraction and preserve orientation), should be placed in 2% glutaraldehyde on ice; this is for electron microscopy.
Investigations and analysis
The types of samples and analyses together with examples of the disorders that may be diagnosed are outlined in Table 2 .
Blood acylcarnitine profiles
The introduction of acylcarnitine pro¢ling on Guthrie card blood spots by electrospray ionization tandem mass spectrometry has revolutionized the investigation of metabolic disease and is the major advance in the post-mortem investigation of these disorders, facilitating the identi¢cation of a wide range of metabolic diseases in tiny samples of blood, plasma and bile. 3 Acylcarnitine pro¢ling has the potential to detect many inherited metabolic defects, including most FAO disorders and many organic acidaemias. 2 Acylcarnitine pro¢les are likely to be more informative when expressed as ratios, as for example, C8/C10 or C8/C12 ratios in the detection of MCAD de¢ciency. 2 This is because post-mortem changes often lead to a non-speci¢c rise in a number of medium-and shortchain acylcarnitines and the expression of results as a ratio gives a more reliable indication of abnormalities resulting from speci¢c defects in FAO. However, few of the pro¢les from post-mortem blood are in themselves reliably diagnostic and further tests, often on ¢bro-blasts, will be needed to con¢rm a diagnosis. As interpretation of acylcarnitine pro¢les can be especially problematic in post-mortem samples, it is always worth seeking out the stored newborn screening Guthrie card (if this is available) for acylcarnitine analysis, as this is potentially more reliably informative.
Blood spot amino acid profiles
Tandem mass spectrometry also allows the identi¢ca-tion of amino acid pro¢les in Guthrie card blood spots in a similar manner as is done with acylcarnitine analysis. This may be particularly useful if larger volumes of liquid blood are not available at postmortem. Such analysis has the potential to identify certain disorders a¡ecting amino acid metabolism/ urea cycle defects 43 even on post-mortem samples (e.g. argininosuccinic acid due to argininosuccinate lyase de¢ciency or citrulline in argininosuccinate synthase de¢ciency). Some other amino acid disorders, such as maple syrup urine disease, are also potentially detectable by blood spot amino acid pro¢ling. FAO defects show high (42.0) NEFA/HB ratios, while hypoglycaemic infants with hyperinsulinism show an inadequate or absent lipolytic and ketogenic response.
Amino acids in plasma, CSF and urine
Aminoacidopathies and urea cycle defects will give abnormal amino acid pro¢les as measured by more conventional amino acid analysis in samples taken prior to death, but, as with Guthrie blood spots, interpretation of post-mortem material is often problematic. Abnormal elevations of certain amino acids may indicate the possibility of speci¢c disorders but need to be interpreted in relation to the interval between death and sampling. Suspected defects of amino acid metabolism will require enzyme/ biochemical con¢rmation in the appropriate tissue or molecular analysis in order to con¢rm a diagnosis. It is worth noting that some urea cycle defects can only be enzymatically con¢rmed on fresh liver biopsy (OTC de¢ciency) or fresh liver or colon (carbamylphosphate synthetase 1 de¢ciency). Mutation analysis circumvents the need for a fresh liver sample in these disorders when a speci¢c diagnosis is strongly suspected.
Organic acids in urine
Organic acidurias, including many of the FAO defects and a signi¢cant number of other defects of intermediary metabolism, will give abnormal organic acid results. Some pro¢les may in themselves be pathognomonic, as in the case of MMA, classical IVA, GA-I or MCAD de¢ciency, but other ¢ndings may be less speci¢c and highlight the need for further investigations. The presence of signi¢cant ketones in urine at post-mortem does not exclude an FAO defect.
Bile
Acylcarnitine and bile acid pro¢les can be measured in small quantities of post-mortem bile, 2,32 but need careful interpretation and require supporting biochemical evidence for accurate diagnosis. Bile acylcarnitine analysis is likely to prove more informative when interpreted in conjunction with a blood spot acylcarnitine pro¢le. Interpretation of post-mortem acylcarnitine pro¢les is best achieved by expression of acylcarnitine ratios. An example of this is in the diagnosis of MCAD de¢ciency (as is the case with blood) where C8/C10 or C8/C12 ratios are far more diagnostically reliable than measurement of octanoylcarnitine alone. 2 
cis-4-Decenoic acid in plasma
This compound is signi¢cantly raised in cases of MCAD de¢ciency and, although not entirely speci¢c for this disorder, is also raised in multiple acyl-CoA dehydrogenase de¢ciency and serves as a very useful indicator of these disorders.
Plasma very long-chain fatty acids and sterols
Very long-chain fatty acids, phytanic acid, pristanic acid and bile acids can be measured in plasma or serum by GC-MS in cases of suspected peroxisomal disorders. Almost all known peroxisomal defects can be detected if all four parameters are measured. Plasma sterol analysis can also be used to detect inherited defects of sterol metabolism (e.g. SmithLemli-Opitz syndrome).
Vitreous humour
Organic acid analysis of eye £uid may be useful in the absence of urine; for example, 7-hydroxyoctanoate is elevated in cases of MCAD de¢ciency, as is octanoylcarnitine. Vitreous humour glucose, provided the sample was taken peri-mortem into a £uoride tube, will re£ect plasma glucose levels at that time. For example, a normal glucose result in an acute admission (provided the patient was not administered glucose prior to death) excludes hypoglycaemia as a cause of collapse.
CSF
Octanoylcarnitine as measured by electrospray ionization tandem mass spectrometry may be usefully measured in CSF in cases of suspected MCAD de¢-ciency. 32 
Molecular investigations
Mutation analysis may be used to con¢rm a diagnosis where enzyme con¢rmation is not possible (e.g. organspeci¢c disease expression of OTC), disorders of structural, receptor or membrane proteins (e.g. sarcomeric proteins in familial cardiomyopathy, 44 detection of mutations in osteogenesis imperfecta) or in diseases with single common mutations (MCAD de¢ciency, long-chain 3-hydroxyacyl-CoA dehydrogenase de¢-ciency). DNA for molecular analysis can be most easily obtained from EDTA whole blood. Guthrie card blood spots, frozen tissue biopsies and ¢broblasts will also yield DNA. If RNA is required this can be obtained from cultured ¢broblasts.
Histochemistry and ultrastructure
The histological or ultrastructural appearance of many tissues can be a good guide to the ¢nal diagnosis but is often non-speci¢c. Staining for micro-and macrovesicular fat and/or glycogen deposition in muscle, heart, liver and kidney at an early stage of the post-mortem process may give an early indication of which lines of investigation to pursue. Evaluation of organ/tissue biopsy using both light and electron microscopy often provides complementary information. Lipid inclusions suggest altered FAO in some glycogen storage diseases (e.g. GSD-I). Increased membrane-bound (i.e. lysosomal) glycogen is typical of Pompe disease (GSD-II). Electron microscopy may show abnormalities in mitochondriopathies such as increased size and number of mitochondria. Giant mitochondria with abnormal or dissociated cristae are characteristic. The mitochondrial matrix may be swollen and display large spherical dense bodies, vacuoles or crystals. Rectangular crystals may be arranged in blocks of parallel crystals with a 'parking lot' con¢guration. However, such changes are not in isolation diagnostic of respiratory chain disease and can only be taken as indicators. Often, particularly in the case of respiratory chain disease, a ¢nal diagnosis is a balance of probabilities based on cumulative clinical, histological and biochemical/molecular evidence.
Tissue assays Cultured fibroblasts
Many of the enzymes known to be de¢cient in inborn errors of metabolism are expressed in skin ¢broblasts, with the notable exception of some urea cycle enzymes and some glycogen storage enzymes. For this reason, obtaining a skin biopsy should be a routine procedure at post-mortem. Homogenates or sonicates of cultured ¢broblasts are suitable for many speci¢c enzyme assays (e.g. glutaryl-CoA dehydrogenase), or alternatively, in some instances, assays using crude mitochondrial preparations may be more appropriate (e.g. the investigation of respiratory chain disorders by polarography). 45 Fibroblasts taken from infants with mitochondrial respiratory chain defects will often express the defect, and low complex(es) II/III or IV may be demonstrated. 46, 47 In some instances, diagnosis can be con¢rmed by mutation analysis of known nuclear genes involved in the assembly of respiratory chain complexes (e.g. SURF1 in systemic cytochrome oxidase de¢ciency presenting as Leigh disease). 48, 49 One particular advantage of using intact living cells is that the uptake or incorporation of various substrates into the cell or the £ux of metabolites through an entire pathway can be measured. 50 Additionally cultured cells have the advantage that they are not subject to deterioration of enzyme activity or secondary loss of function, which is so frequently a problem in biopsies and particularly other post mortem samples. An example of the use of intact cells is in the diagnosis of fatty acid oxidation disorders by tritiated release assay in cultured ¢broblasts. 51 More recently cultured ¢broblasts have been incubated with deuterium labelled fatty acids or other suitable substrates and the resultant acylcarnitine pro¢les analysed by tandem mass spectrometry. 52 This latter technique has proved to be particularly informative in fatty acid oxidation disorders, but also has the potential for use in a wide range of other inherited metabolic diseases.
Other tissues
Fresh frozen muscle is often the tissue of choice for the diagnosis of mitochondrial respiratory chain disorders. Provided the muscle has been collected prior to death (or within 2 h of death), complexes I, II, III and IV of the respiratory chain can be measured. 45 Other tissues such as heart and liver can also be used where speci¢c involvement of these tissues is indicated, such as mutation analysis of cardiac mitochondrial tRNAs in the case of isolated cardiomyopathy 53 or speci¢c enzyme assay in fresh liver for some urea cycle and glycogen storage disorders.
Conclusion
The application of electrospray ionization tandem mass spectrometry to clinical chemistry o¡ers the opportunity for detailed biochemical analysis in tiny samples of blood, plasma and bile. This technique coupled with recent advances in molecular genetics now greatly improves the chances of accurate postmortem diagnosis for a wide range of inherited metabolic diseases. This process relies on the timely collection of suitable post-mortem samples and careful review of any pre-mortem laboratory results that may be helpful in the subsequent selection of further laboratory testing.
In many cases where there is a suspicion of an underlying metabolic cause of death, it is strongly advised that, wherever possible, the neonatal screening card should be analysed for acylcarnitines and, if indicated, for amino acid analysis also. These analyses carried out on the neonatal Guthrie card blood spot generally provide a more reliable indicator of many metabolic diseases than analyses performed on post-mortem samples.
